GET DAILY SIGNALSBio-Rad Laboratories (BIO) Q3 2026 Earnings Preview: Modest Declines in Focus
Key Takeaways
- Bio-Rad Laboratories (BIO) is scheduled to report its third-quarter 2026 results on Wednesday, November 4, 2026, after the market close.
- Wall Street consensus points to non-GAAP earnings of about $2.23 per share on revenue near $649.9 million.
- Those expectations imply modest declines versus the prior-year quarter, when the company posted non-GAAP EPS of $2.26 on revenue of $653.0 million.
- In the most recent quarter (Q2 2026), revenue of $651.0 million was roughly flat year over year, while non-GAAP EPS of $2.62 comfortably beat the $1.75 consensus.
- Investors will focus on the Life Science segment's recovery, digital PCR (dPCR) momentum, China headwinds, and any updates to full-year 2026 guidance.
Why This Earnings Report Matters
Bio-Rad Laboratories (BIO) provides life science research and clinical diagnostics products, so its quarterly results give insight into spending trends across academic, biopharma, and diagnostic markets. The third-quarter print is notable because the company continues to navigate uneven demand: Clinical Diagnostics has shown modest growth, while Life Science has dealt with softness in academic research. Full-year 2026 guidance calls for roughly flat currency-neutral revenue and a lower non-GAAP operating margin, making this report a test of whether earlier stabilization signs are holding up.
Analyst Expectations for Q3
Analysts expect Bio-Rad to report non-GAAP earnings of approximately $2.23 per share on revenue of about $649.9 million for the third quarter of 2026. That compares with non-GAAP EPS of $2.26 on revenue of $653.0 million in the same quarter a year ago, pointing to a roughly 1.3% decline in earnings per share and a roughly 0.5% decline in revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. These muted forecasts come after a second quarter in which revenue of $651.0 million was essentially flat as reported and down 1.9% on a currency-neutral basis, with non-GAAP EPS of $2.62 beating the $1.75 consensus. For the full year, management still expects currency-neutral revenue in a range from a decline of about 3.0% to growth of about 0.5%, alongside a non-GAAP operating margin of roughly 10.0% to 12.0%.
Investor Sentiment Ahead of the Print
Sentiment leading into the report is cautious yet attentive. The stock has traded below recent highs as investors weigh a multi-year period of uneven revenue growth, academic market softness, and ongoing China headwinds. In the prior quarter, management noted high-teens revenue declines in China and an estimated $4 million headwind for the rest of 2026. Key areas of focus include the pace of recovery in academic and government research spending, the strength of dPCR instrument demand, and whether currency-neutral revenue can reach the upper end of the full-year range.
Key Factors to Monitor After the Release
Investors will pay close attention to any updates on full-year 2026 guidance, given the narrow range of currency-neutral revenue expectations from negative 3.0% to positive 0.5% and a non-GAAP operating margin target of 10.0% to 12.0%. The Life Science segment remains central, as it has been the main drag on growth; signs of stabilization in biopharma and academic markets would be positive. Digital PCR instrument sales, which grew more than 20% in the second quarter, continue to be a potential longer-term support. Cost execution also matters, with a restructuring program expected to deliver $30 million to $35 million in annualized net savings by the end of 2027 and 40 to 50 basis points of operating margin expansion. Progress on those savings, China demand trends, and any shifts in the Sartorius AG investment will be worth tracking.
My Take on Using Tickeron Tools
In preparing for earnings like this one from Bio-Rad Laboratories, I often rely on Tickeron’s AI Screener to quickly filter comparable names in the life sciences space and review technical patterns alongside fundamentals. It helps surface context on volatility and recent performance without spending hours on manual checks, which keeps my process efficient when monitoring multiple reports in a given week.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BIO's Indicator enters downward trend
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator formed such a pattern. In 155 of the 202 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIO as a result. In 67 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
BIO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Oscillator exited the oversold zone, 21 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.344) is normal, around the industry mean (2.923). P/E Ratio (43.803) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of life science research products and clinical diagnostics
Industry MedicalNursingServices
Advertisement